연구성과로 돌아가기
2021 연구자 정보 (32 / 1146)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Jo, E. (Jo, E) |
Pusan Natl Univ, Pusan Natl Univ Hosp, Dept Internal Med, Coll Med, Busan, South Korea |
|
|
[JCR상위 1.8] The clinical burden in systemic corticosteroid-independent asthmatics with high blood eosinophil counts: COREA cohort in Korea | SCIE | 1.8 | ALLERGY;IMMUNOLOGY | |||
|
Jung, Chang-Gyu (Jung, CG) |
Keimyung Univ, Dongsan Hosp, Dept Internal Med, Div Allergy & Clin Immunol, Daegu, South Korea |
|
|
[JCR상위 1.8] Characterization of asthma and risk factors for delayed SARS-CoV-2 clearance in adult COVID-19 inpatients in Daegu | SCIE | 1.8 | ALLERGY;IMMUNOLOGY | jhj0619@yu.ac.kr;haan33@gmail.com; | ||
|
Jung, H. A. (Jung, HA) |
Sungkyunkwan Univ, Div Hematol Oncol, Dept Med, Samsung Med Ctr,Sch Med, Seoul, South Korea Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul, South Korea |
|
|
[JCR상위 1.8] Sequential afatinib (afa) and osimertinib (osi) in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) NSCLC who acquire the T790M resistance mutation: A non-interventional cohort study (UpSwinG) [JCR상위 5.1] Sequential Afatinib and Osimertinib in Patients With Advanced EGFRm plus NSCLC and Acquired T790M: The Real-World UpSwinG study |
SCIE | 1.8 |
ONCOLOGY ONCOLOGY;RESPIRATORY SYSTEM |
|||
|
Jung, J. (Jung, J) |
Chung Ang Univ, Dept Internal Med, Coll Med, Seoul, South Korea |
|
|
[JCR상위 1.8] The clinical burden in systemic corticosteroid-independent asthmatics with high blood eosinophil counts: COREA cohort in Korea | SCIE | 1.8 | ALLERGY;IMMUNOLOGY | |||
|
Kim, S. J. (Kim, SJ) |
Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Sch Med, Seoul, South Korea |
|
|
[JCR상위 1.8] Combination treatment of copanlisib and gemcitabine in relapsed refractory PTCL (COSMOS): an open-label phase I/II trial | SCIE | 1.8 | ONCOLOGY | jhmoon@knu.ac.kr;drydb1685@hotmail.com;drydh1685@hotmail.com; | ||
|
Kim, Sujeong (Kim, S) |
제1저자 |
Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Div Allergy & Clin Immunol, Dept Internal Med,Sch Med, Daegu, South Korea Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Internal Med, Daegu, South Korea Kyungpook Natl Univ, Dept Internal Med, Sch Med, Daegu, South Korea Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea |
N-1450-2019 J-2749-2012 Kim, Ju-Hyoung Kim, Jong |
0000-0002-2494-9216 Kim, Sujeong |
[JCR상위 1.8] Characterization of asthma and risk factors for delayed SARS-CoV-2 clearance in adult COVID-19 inpatients in Daegu [JCR상위 31.3] Quantitative CT image-based structural and functional changes during asthma acute exacerbations [JCR상위 8.9] Reintroduction of Antituberculous Drugs in Patients with Antituberculous Drug-Related Drug Reaction with Eosinophilia and Systemic Symptoms [JCR상위 5.4] Lung virome: New potential biomarkers for asthma severity and exacerbation [JCR상위 37.5] Risk factors of beta-lactam anaphylaxis in Korea: A 6-year multicenter retrospective adult case-control study [JCR상위 44.8] Severe Cutaneous Adverse Reactions to Anti-tuberculosis Drugs in Korean Patients [JCR상위 8.9] A Randomized, Noninferiority Trial Comparing ICS thorn LABA with ICS plus LABA plus LAMA in Asthma-COPD Overlap (ACO) Treatment: The ACO Treatment with Optimal Medications (ATOMIC) Study [JCR상위 8.9] A Nationwide Study of Severe Cutaneous Adverse Reactions Based on the Multicenter Registry in Korea |
SCIE | 1.8 |
ALLERGY;IMMUNOLOGY PHYSIOLOGY;SPORT SCIENCES |
jhj0619@yu.ac.kr;haan33@gmail.com; changhyun.lee@snu.ac.kr;s-choi@knu.ac.kr; helenmed@snu.ac.kr; helenmed@snu.ac.kr;hanayi@korea.ac.kr; parkhk@puan.ac.kr;helenmed@snu.ac.kr; parkhk@pusan.ac.kr; tbkim@amc.seoul.kr; |
|
|
Kim, W. S. (Kim, WS) |
Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Sch Med, Seoul, South Korea |
|
|
[JCR상위 1.8] Combination treatment of copanlisib and gemcitabine in relapsed refractory PTCL (COSMOS): an open-label phase I/II trial | SCIE | 1.8 | ONCOLOGY | jhmoon@knu.ac.kr;drydb1685@hotmail.com;drydh1685@hotmail.com; | ||
|
Koh, Y. (Koh, Y) |
Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea |
|
|
[JCR상위 1.8] Combination treatment of copanlisib and gemcitabine in relapsed refractory PTCL (COSMOS): an open-label phase I/II trial | SCIE | 1.8 | ONCOLOGY | jhmoon@knu.ac.kr;drydb1685@hotmail.com;drydh1685@hotmail.com; | ||
|
Kwon, J. W. (Kwon, JW) |
Kangwon Natl Univ, Dept Internal Med, Sch Med, Chunchon, South Korea |
|
|
[JCR상위 1.8] The clinical burden in systemic corticosteroid-independent asthmatics with high blood eosinophil counts: COREA cohort in Korea | SCIE | 1.8 | ALLERGY;IMMUNOLOGY | |||
|
Lee, M. K. (Lee, MK) |
Pusan Natl Univ, Dept Internal Med, Sch Med, Busan, South Korea Pusan Natl Univ, Sch Med, Dept Internal Med, Busan, South Korea |
|
|
[JCR상위 1.8] Sequential afatinib (afa) and osimertinib (osi) in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) NSCLC who acquire the T790M resistance mutation: A non-interventional cohort study (UpSwinG) [JCR상위 5.1] Sequential Afatinib and Osimertinib in Patients With Advanced EGFRm plus NSCLC and Acquired T790M: The Real-World UpSwinG study |
SCIE | 1.8 |
ONCOLOGY ONCOLOGY;RESPIRATORY SYSTEM |
|||
|
Lee, S. H. (Lee, SH) |
Kyung Hee Univ, Med Ctr, Div Pulm & Crit Care Med, Dept Internal Med,Sch Med, Seoul, South Korea Kyung Hee Univ, Div Pulm & Crit Care Med, Dept Internal Med, Med Ctr,Sch Med, Seoul, South Korea Inst Basic Sci IBS, Ctr Underground Phys, Daejeon 34126, South Korea Univ Sci & Technol UST, IBS Sch, Daejeon 34113, South Korea |
IUN-3410-2023 AAS-8066-2021 Lee, Yo Han Lee, Seunghyun |
|
[JCR상위 1.8] Sequential afatinib (afa) and osimertinib (osi) in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) NSCLC who acquire the T790M resistance mutation: A non-interventional cohort study (UpSwinG) [JCR상위 5.1] Sequential Afatinib and Osimertinib in Patients With Advanced EGFRm plus NSCLC and Acquired T790M: The Real-World UpSwinG study [JCR상위 66.2] The COSINE-100 liquid scintillator veto system [JCR상위 13.8] Measurement of the cosmic muon annual and diurnal flux variation with the COSINE-100 detector [JCR상위 51.5] Lowering the energy threshold in COSINE-100 dark matter searches [JCR상위 25.9] Background modeling for dark matter search with 1.7 years of COSINE-100 data [JCR상위 25.9] Identification of new isomers in ²²⁸Ac: impact on dark matter searches |
SCIE | 1.8 |
ONCOLOGY ONCOLOGY;RESPIRATORY SYSTEM INSTRUMENTS & INSTRUMENTATION;NUCLEAR SCIENCE & TECHNOLOGY;PHYSICS, NUCLEAR;PHYSICS, PARTICLES & FIELDS ASTRONOMY & ASTROPHYSICS;PHYSICS, PARTICLES & FIELDS PHYSICS, PARTICLES & FIELDS |
jayhyun.jo@yale.edu; hafizh@ibs.re.kr; chha@cau.ac.kr;yjko@ibs.re.kr; ejjeon@ibs.re.kr;yjko@ibs.re.kr; yjko@ibs.re.kr;hyunsulee@ibs.re.kr; |
||
|
Lee, S. Yup (Lee, SY) |
Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea |
|
|
[JCR상위 1.8] Sequential afatinib (afa) and osimertinib (osi) in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) NSCLC who acquire the T790M resistance mutation: A non-interventional cohort study (UpSwinG) | SCIE | 1.8 | ONCOLOGY | |||
|
Lee, Y. C. (Lee, YC) |
Chonbuk Natl Univ, Res Inst Clin Med, Chonbuk Natl Univ Hosp, Dept Internal Med,Med Sch,Biomed Res Inst, Jeonju, South Korea Chonbuk Natl Univ, Chonbuk Natl Univ Hosp, Res Inst Clin Med, Biomed Res Inst,Dept Internal Med,Med Sch, Jeonju, South Korea |
|
|
[JCR상위 1.8] Sequential afatinib (afa) and osimertinib (osi) in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) NSCLC who acquire the T790M resistance mutation: A non-interventional cohort study (UpSwinG) [JCR상위 5.1] Sequential Afatinib and Osimertinib in Patients With Advanced EGFRm plus NSCLC and Acquired T790M: The Real-World UpSwinG study |
SCIE | 1.8 |
ONCOLOGY ONCOLOGY;RESPIRATORY SYSTEM |
|||
|
Maerten, A. (Märten, A) |
Boehringer Ingelheim Int GmbH, TA Oncol Med, Ingelheim, Germany |
|
|
[JCR상위 1.8] Sequential afatinib (afa) and osimertinib (osi) in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) NSCLC who acquire the T790M resistance mutation: A non-interventional cohort study (UpSwinG) | SCIE | 1.8 | ONCOLOGY | |||
|
Migliorino, M. R. (Migliorino, MR) |
San Camillo Forlanini Hosp, Pulm Oncol Unit, Rome, Italy San Camillo Forlanini Hosp, Rome, Italy |
|
|
[JCR상위 1.8] Sequential afatinib (afa) and osimertinib (osi) in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) NSCLC who acquire the T790M resistance mutation: A non-interventional cohort study (UpSwinG) [JCR상위 5.1] Sequential Afatinib and Osimertinib in Patients With Advanced EGFRm plus NSCLC and Acquired T790M: The Real-World UpSwinG study |
SCIE | 1.8 |
ONCOLOGY ONCOLOGY;RESPIRATORY SYSTEM |
페이지 이동: